Calendario›CTNM›PIPE-791
PIPE-791
Study of PIPE-791 for Subjects With Chronic Osteoarthritis Pain or Chronic Low Back Pain
Ensayo de Contineum Therapeutics, Inc. en Chronic Osteoarthritis Pain · Chronic Low Back Pain (del registro, en inglés).
Lo que ha anunciado la empresa
La empresa anunció que alcanzó su objetivo principalEX-99.1 2 a8-kpaindataex991.htm EX-99.1 Exhibit 99.1 CONTINEUM THERAPEUTICS REPORTS POSITIVE TOPLINE DATA FROM ITS EXPLORATORY PIPE-791 PHASE 1B TRIAL IN CHRONIC PAIN –The trial achieved its primary endpoint demonstrating favorable safety and tolerability –Encouraging trends observed across multiple exploratory efficacy endpoints including improvements in measures of pain and other functional patient-reported…
En un 8-K del 30 abr 2026, en una frase que nombra «PIPE-791». El documento en la SEC.
- Fase
- Fase 1
- Estado
- Completado
- Participantes
- 43
- Centros
- 5
- Fin del objetivo primario
- ene 2026
Qué significa cada fase y cada estado.
Estudio de intervención, aleatorizado, cuádruple ciego. Comenzó en feb 2025.
Qué mide
Number of subjects with Treatment-emergent adverse events (TEAEs) (For Treatment Period 1, from Baseline (Day 1) to End of Treatment Period 1 (TP1; Day 29), for Treatment Period 2, from Baseline of Treatment Period 2 (TP2; Day 29) to End of TP2 (Day 57).) (del registro, en inglés)
Cómo lo describe el promotor
En el documentoEn inglés, del registroThe primary goal of this clinical trial is to learn if PIPE-791 is safe and well-tolerated in adults with chronic osteoarthritis pain (COAP) or chronic low back pain (CLBP). The study will also explore whether PIPE-791 lowers pain in people with COAP or CLBP. Subjects will: * Complete a washout period to stop their current pain medications. * Take a daily dose of PIPE-791 or placebo for 4 weeks, then reverse treatment assignment for another 4 weeks. * Record pain levels and track dosing in a daily e-diary. * Visit the clinic for checkups and lab tests throughout the study. * Complete phone assessments during the treatment periods.
Más ensayos de CTNM
| Ensayo | Fase | Estado | Lectura de resultados |
|---|---|---|---|
| PIPE-791 Dose A | Fase 2 | Reclutando pacientes | may 2028 (prevista) |
| PIPE-791 | Fase 1 | Completado | jun 2025 (real) |
| PIPE-791 | Fase 1 | Completado | feb 2024 (real) |
| PIPE-307 | Fase 1 | Completado | nov 2021 (real) |
| PIPE-307 | Fase 1 | Completado | sep 2021 (real) |
| PIPE-505 | Fase 1/2 | Completado | jun 2021 (real) |
Todos los de CTNM, en su ficha.
Ficha completa en ClinicalTrials.gov (NCT06810245), actualizada en mar 2026.